DK3127545T3 - Antitumorlægemiddel, der indeholder taxanforbindelse, og anti- tumorvirkningsfremmer - Google Patents

Antitumorlægemiddel, der indeholder taxanforbindelse, og anti- tumorvirkningsfremmer Download PDF

Info

Publication number
DK3127545T3
DK3127545T3 DK15774351.9T DK15774351T DK3127545T3 DK 3127545 T3 DK3127545 T3 DK 3127545T3 DK 15774351 T DK15774351 T DK 15774351T DK 3127545 T3 DK3127545 T3 DK 3127545T3
Authority
DK
Denmark
Prior art keywords
compound
medicine containing
antitumor medicine
efficiency promoter
tumor efficiency
Prior art date
Application number
DK15774351.9T
Other languages
English (en)
Inventor
Hiroyuki Okabe
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK3127545T3 publication Critical patent/DK3127545T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK15774351.9T 2014-04-04 2015-04-03 Antitumorlægemiddel, der indeholder taxanforbindelse, og anti- tumorvirkningsfremmer DK3127545T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014078243 2014-04-04
PCT/JP2015/060645 WO2015152409A1 (ja) 2014-04-04 2015-04-03 タキサン系化合物を含有する抗腫瘍剤及び抗腫瘍効果増強剤

Publications (1)

Publication Number Publication Date
DK3127545T3 true DK3127545T3 (da) 2020-08-10

Family

ID=54240716

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15774351.9T DK3127545T3 (da) 2014-04-04 2015-04-03 Antitumorlægemiddel, der indeholder taxanforbindelse, og anti- tumorvirkningsfremmer

Country Status (14)

Country Link
US (1) US20170112866A1 (da)
EP (1) EP3127545B1 (da)
JP (1) JP6488280B2 (da)
AU (1) AU2015242788B2 (da)
DK (1) DK3127545T3 (da)
ES (1) ES2806449T3 (da)
HU (1) HUE051014T2 (da)
NZ (1) NZ725303A (da)
PL (1) PL3127545T3 (da)
PT (1) PT3127545T (da)
RU (1) RU2693463C2 (da)
UA (1) UA120611C2 (da)
WO (1) WO2015152409A1 (da)
ZA (1) ZA201607067B (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102216772B1 (ko) * 2018-05-18 2021-02-17 주식회사 종근당 혈관차단제 및 탁산 화합물을 포함하는 암 예방 또는 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1485127E (pt) * 2002-02-25 2011-09-07 Elan Pharm Inc Administração de agentes para o tratamento de inflamação
BRPI0515774A (pt) * 2004-12-15 2008-08-05 Novartis Ag combinações de agentes terapêuticos para o tratamento de cáncer
US7799783B2 (en) * 2005-01-26 2010-09-21 Taiho Pharmaceutical Co., Ltd. Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
EP2509592A1 (en) * 2009-12-07 2012-10-17 Boehringer Ingelheim International GmbH Bibw 2992 for use in the treatment of triple negative breast cancer
KR20190143480A (ko) * 2010-02-23 2019-12-30 제넨테크, 인크. 난소암의 치료를 위한 항혈관신생 요법
EP2740477A1 (en) * 2011-08-02 2014-06-11 Astellas Pharma Inc. Method for treating cancer by combined use of medicinal agents
SG11201502941VA (en) * 2012-10-17 2015-05-28 Vascular Biogenics Ltd Treatment methods using adenovirus

Also Published As

Publication number Publication date
AU2015242788A1 (en) 2016-11-17
NZ725303A (en) 2019-02-22
JP6488280B2 (ja) 2019-03-20
UA120611C2 (uk) 2020-01-10
RU2016143243A (ru) 2018-05-07
PL3127545T3 (pl) 2020-11-16
PT3127545T (pt) 2020-07-20
US20170112866A1 (en) 2017-04-27
ZA201607067B (en) 2017-09-27
EP3127545A1 (en) 2017-02-08
EP3127545A4 (en) 2017-11-22
WO2015152409A1 (ja) 2015-10-08
ES2806449T3 (es) 2021-02-17
RU2693463C2 (ru) 2019-07-03
HUE051014T2 (hu) 2021-01-28
AU2015242788B2 (en) 2018-10-25
JPWO2015152409A1 (ja) 2017-04-13
EP3127545B1 (en) 2020-06-03
RU2016143243A3 (da) 2018-07-17

Similar Documents

Publication Publication Date Title
DK3188717T3 (da) Formulering, der omfatter partikler
EP3094342A4 (en) Anti-tumor therapy
GB201600789D0 (en) Concentric pumped riser solution
DK3158847T3 (da) Bæreanordning
GB201415163D0 (en) Laminated glazing
GB201502252D0 (en) Carrier
DK3094579T3 (da) Bånd-på-bånd transportør
AP2016009629A0 (en) Shale gas extraction
DE112016000932A5 (de) Radträger
PT3144626T (pt) Estrutura de transporte pirotécnico
GB201410723D0 (en) Proppants
DK3253749T3 (da) Forbindelser med antitumoraktivitet
DK3127545T3 (da) Antitumorlægemiddel, der indeholder taxanforbindelse, og anti- tumorvirkningsfremmer
DK3178837T3 (da) Urlc10-afledt peptid og vaccine, der indeholder dette
EP3111944A4 (en) Antiviral drug
LT3127544T (lt) Priešnavikinis vaistas, kurio sudėtyje yra priešnavikinis platinos kompleksas ir priešnavikinio poveikio stipriklis
GB201415857D0 (en) Laminated structure
GB201505681D0 (en) Submersible aircraft carrier etc.
ZA201507927B (en) Taxi hearse
UA32452S (uk) Круг алмазний
UA32451S (uk) Круг алмазний
CL2014002008S1 (es) Portaequipaje
CL2014002007S1 (es) Portaequipaje
FI20140043L (fi) Menetelmä tuottaa puhdasta perfluorodekaliinia
ES1113105Y (es) Estructura metalica.